NQO1 antibody [A180] (ab28947)

Product Name 

NQO1 antibody [A180]

Product type 

Primary antibodies

Description 

Mouse monoclonal [A180] to NQO1

Immunogen 

Recombinant full length protein of Human NQO1.

Reacts with 
(species key)

Hu, Ms, Rat

Tested applications 
(see key)

ICC/IF, IHC-P, IP, WB, sELISA

Abreviews 

Customer reviews (see key)

Read about Abreviews (Read all Abreviews)

Application notes 
(see key)

Recommended dilutions
ICC/IF: Use at a concentration of 1 µg/ml.
IHC-P: Use at an assay dependent dilution.
IP: Use at an assay dependent dilution.
sELISA: 1/500. Can be used as capture antibody in conjunction with ab34173 as detection antibody.
WB: Use at a concentration of 1 µg/ml. Predicted molecular weight: 30 kDa.

Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Cellular localization 

Cytoplasmic

Research areas 

Signal Transduction >> Metabolism >> Drug metabolism

Relevance 

NQO1 is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. NQO1 functions as an important part of cellular antioxidant defense by detoxifying quinones thus preventing the formation of reactive oxygen species. Mutations in the gene for NQO1 have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD).
NQO1 levels have been shown to be raised in may tumour types. This has led to a search for anti-tumour agents that can be activated by NQO1 resulting in specific targetting of these compounds to the tumour site. Many cytotoxic drugs contain the quinone moiety, such as the benzoquinone group, which can be activated by NQO1 through the reduction into hydroquinone [which in this case can auto-oxidize and lead to the formation of free radicals and alkylating species]. However, the rat enzyme has been shown to be significantly more effective in activating some of these compounds than the human and mouse enzymes. This indicates that the available cytotoxic drugs are better substrates for the rat enzyme and are not the most ideal prodrugs for activation by NQO1 in human tumors.

Database links 

Raised in 

Mouse

Clonality 

Monoclonal

Clone number 

A180

Isotype 

IgG1

Purity 

Protein A purified

Storage buffer 

Preservative: 0.02% Sodium Azide
Constituents: PBS, pH 7.4

Material safety datasheet (MSDS) for this product:
Sodium Azide MSDS

Form 

Liquid

Concentration 

1.000 mg/ml

Storage instructions 

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

See below for NQO1 antibody [A180] images, references, products related to ab28947 and other tools.

NQO1 antibody [A180] images:

References for NQO1 antibody [A180] (ab28947)

  This product has been used in: (two most recent references)

Yang L et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 4:e5757 (2009). WB; Human. PubMed: 19484125

Cleton-Jansen AM et al. ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer 8:105 (2008). PubMed: 18416817

See all 14 publication references for this product.


If you publish research using ab28947 please let us know so that we can cite the reference on this datasheet.

Customer reviews (feedback) regarding NQO1 antibody [A180]

Customer FAQs regarding NQO1 antibody [A180]

Protocols for NQO1 antibody [A180]

Price and availability of products related to NQO1 antibody [A180]

NQO1 antibody [A180] - related products: